Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - indium (111in) chloride, quantity: 370 mbq/ml - injection, solution - excipient ingredients: hydrochloric acid - for the radiolabelling of approved polyaminocarboxylic acid derivatised monoclonal antibody preparations for in vivo diagnostic imaging procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - indium (111in) chloride, quantity: 370 mbq/ml - injection, solution - excipient ingredients: hydrochloric acid - for the radiolabelling of approved polyaminocarboxylic acid derivatised monoclonal antibody preparations for in vivo diagnostic imaging procedures.

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium molybdate (99mo); sodium pertechnetate (99mtc) - injection - 2.5-100 gbq/generator - sodium molybdate (99mo) 2.5-100 gbq/generator; sodium pertechnetate (99mtc) variable

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amersham health a.s., norway - mangafodipir trisodium - solution - 7.57 mg/ml

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 30 g in 100 ml - hypaque-cysto is indicated for retrograde cystourethrography in adult and pediatric patients. hypaque-cysto has no absolute contraindication in its recommended use.

Ireland - English - HPRA (Health Products Regulatory Authority)

amersham health srl - human albumin macro aggregated - unknown

Ireland - English - HPRA (Health Products Regulatory Authority)

amersham health srl - human albumin macro aggregated - unknown

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 500 mg in 1 ml - hypaque sodium 50 percent is indicated for excretory urography, cerebral and peripheral angiography, aortography, intraosseous venography, direct cholangiography, hysterosalpingography, splenoportography, and contrast enhancement of computed tomographic head imaging. diatrizoate salts are used in small, medium, and large dose urography (see dosage and administration—excretory urography). visualization of the urinary tract can be achieved by either direct intravenous bolus injection, intravenous drip infusion, or incidentally following intra-arterial procedures.visualization of the urinary tract is delayed in infants less than 1 month old, and in patients with urinary tract obstruction (see clinical pharmacology). injectable radiopaque contrast media may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. radiopaque diagnostic agents may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malig

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 60 g in 100 ml - hypaque meglumine 60 percent is indicated for excretory urography; cerebral angiography; peripheral arteriography; venography; operative, t-tube, or percutaneous transhepatic cholangiography; splenoportography; arthrography; discography; and contrast enhancement of computed tomographic head imaging. diatrizoate salts are used in small, medium, and large dose urography (see dosage and administration-excretory urography). visualization of the urinary tract can be achieved by either direct intravenous bolus injection, intravenous drip infusion, or incidentally following intra-arterial procedures. visualization of the urinary tract is delayed in infants less than 1 month old, and in patients with urinary tract obstruction (see clinical pharmacology). injectable radiopaque contrast media may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. radiopaque diagnostic agents may be useful to investigate the presence and extent of certain malignancie

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoate - unii:), diatrizoate sodium (unii: v5403h8vg7) (diatrizoate - unii:) - injection, solution - 660 mg in 1 ml - hypaque-76 is indicated for excretory urography, aortography, angiocardiography (ventriculography, pulmonary angiography, selective coronary arteriography), peripheral angiography (peripheral arteriography and peripheral venography), intravenous digital arteriography, contrast enhancement of computed tomographic head imaging, contrast enhancement of computed tomographic body imaging, selective renal arteriography, selective visceral arteriography, central venography, and renal venography. in addition to the following generalcontraindications, warnings, precautions, and adverse reactions, there are additional listings in these categories under the particular procedures. hypaque-76 has no absolute contraindications in its recommended uses (see general warnings and precautions). do not use hypaque-76 for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. even a small amount in the subarachnoid space may produce convulsions and result in fatality. (see